In a research report released on Wednesday, Cowen analyst Ritu Baral initiated coverage on shares of Cytokinetics Inc. (NASDAQ:CYTK) with an Outperform rating and …
Cytokinetics, Inc. (NASDAQ:CYTK) and The ALS Association announced that The Association has awarded Cytokinetics a $1.
I’ve written about Cytokinetics, Inc. (NASDAQ:CYTK), a biopharmaceutical company that is the industry leader in developing drugs that modulate muscle function, a …
In a research report sent to investors today, MLV analyst George Zavoico reiterated a Buy rating on Cytokinetics, Inc. (NASDAQ:CYTK) with a $9.
In a research report released yesterday, MLV analyst George Zavoico upgrades shares of Cytokinetics (NASDAQ:CYTK) from a Hold to a Buy rating and increased his …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) with a $13 price target, which represents a potential upside of 233% …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) with a price target of $13, as the company provided an update regarding its cardiac …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics Inc. (CYTK) with a $13 price target, following CYTK’s second quarter earnings …
In a research report published yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytokinetics Inc. (CYTK) with a $13 price …
